Canakinumab
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-16 — Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.: CANFIRE phase-2 open-label multicenter trial (early-terminated for poor accrual): no patient achieved IWG 2018 HI-E in lower-risk MDS/MDS-MPN; well tolerated with no SAEs or deaths, arguing against IL-1β blockade alone as an anemia-reversing strategy in this setting. (novelty: 3)
Open questions
Related
Contributing findings
Canakinumab or emavusertib for anemia in lower-risk MDS: results of the CANFIRE and LUCAS phase 2, open-label, multicenter trials.
16-sep-2026
novelty 3
per-area 3
weakens